Concizumab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Concizumab in hemophilia with inhibitors: Longer-term efficacy and safety results from the phase 3 explorer7 study.

Concizumab in hemophilia with inhibitors: Longer-term efficacy and safety results from the phase 3 explorer7 study.

Journal: Blood advances

Published: September 03, 2025

Concizumab use in toddlers with hemophilia B and inhibitors real-world data from an international collaboration.

Concizumab use in toddlers with hemophilia B and inhibitors real-world data from an international collaboration.

Journal: Journal of thrombosis and haemostasis : JTH

Published: July 15, 2025

Rebalancing therapy for congenital hemophilia

Rebalancing therapy for congenital hemophilia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: July 06, 2025

Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.

Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context.

Journal: Biomedicines

Published: July 06, 2025

Fitusiran (Qfitlia) for hemophilia A and B.

Fitusiran (Qfitlia) for hemophilia A and B.

Journal: The Medical letter on drugs and therapeutics

Published: July 02, 2025

Pharmacokinetic evaluation of concizumab for the treatment of hemophilia.

Pharmacokinetic evaluation of concizumab for the treatment of hemophilia.

Journal: Expert opinion on drug metabolism & toxicology

Published: June 23, 2025

Anti-tissue factor pathway inhibitors for hemophilia: are these treatments the answer to overcoming current treatment limitations?

Anti-tissue factor pathway inhibitors for hemophilia: are these treatments the answer to overcoming current treatment limitations?

Journal: Expert review of hematology

Published: June 14, 2025

Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties.

Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties.

Journal: Haematologica

Published: May 16, 2025

Evaluating the Safety and Efficacy of Concizumab in Hemophilia A/B Patients: A Systematic Review.

Evaluating the Safety and Efficacy of Concizumab in Hemophilia A/B Patients: A Systematic Review.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: May 14, 2025

Concizumab (Alhemo) for hemophilia A and B with inhibitors.

Concizumab (Alhemo) for hemophilia A and B with inhibitors.

Journal: The Medical letter on drugs and therapeutics

Published: May 05, 2025

Revolutionizing Treatment Strategies through Inhibition of Tissue Factor Pathway Inhibitor: A Promising Therapeutic Approach for Hemophilia Management.

Revolutionizing Treatment Strategies through Inhibition of Tissue Factor Pathway Inhibitor: A Promising Therapeutic Approach for Hemophilia Management.

Journal: The Journal of the Association of Physicians of India

Published: April 09, 2025

Erratum: The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference [Corrigendum].

Erratum: The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference [Corrigendum].

Journal: Patient preference and adherence

Published: March 19, 2025

Showing 1-12 of 75

Last Updated: 02/24/2026